Navigation Links
Algenol Biofuels Further Strengthens Team With Key Appointments
Date:9/15/2008

Greg Schlicht and Dax Denman Join as Company Enters Commercialization Phase

NAPLES, Fla., Sept. 15 /PRNewswire/ -- Algenol Biofuels, developers of DIRECT TO ETHANOL(TM), the most advanced third generation biofuels technology, today announced the continued growth of the company with the appointments Greg Schlicht as Senior Vice President of Business Development and General Counsel and Dax Denman as Senior Program Manager.

Mr. Schlicht will be working with Algenol's partners to commercialize the Algenol process and will oversee select corporate legal matters for the Company. He joins the company from VeraSun Energy where he was part of the company's executive team as senior vice president, general counsel and corporate secretary. Prior to VeraSun's merger with US BioEnergy, Schlicht was responsible at US BioEnergy for establishing a corporate legal department, adopting corporate governance practices, and managing the legal process for plant acquisitions, in addition to overseeing major project financings to fund construction of new ethanol plants. Mr. Schlicht will be based in Naples, Florida and will report to Paul Woods, CEO of Algenol.

Dax Denman joins Algenol as a senior program manager and will oversee the work being conducted at Algenol's numerous labs and facilities. Prior to joining Algenol he was senior project manager at Amgen. Mr. Denman brings over 10 years experience from the bio-pharmaceutical industry commercializing recombinant therapeutic proteins through his work as a research scientist with Bayer Healthcare, and as project manager supporting technology transfer of commercial processes to Ireland, Germany, and Puerto Rico with Wyeth Pharmaceuticals. Mr. Denman holds a B.S. in Microbiology from Indiana University and a M.S. in Molecular Physiology from the University of Virginia. Mr. Denman will be based in Naples, Florida and report to Dr. Craig Smith, COO of Algenol.

Paul Woods, co-founder and CEO of Algenol Biofuels,
'/>"/>

SOURCE Algenol Biofuels, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Algenol Biofuels Appoints Chief Science Officer
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
4. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
5. Healthcare Technologies Ltd. Announces the Change of its Name to "NexGen Biofuels Ltd"
6. NexGen Biofuels Ltd. (Nasdaq: NXGN) Announces Receipt of Nasdaq Delisting Determination
7. NexGen Biofuels Ltd. Announces Trading on OTC Bulletin Board
8. Monsanto Company and Mendel Biotechnology Announce Cellulosic Biofuels Collaboration
9. Performance Plants Establishes U.S. Biofuels Facility
10. NexGen Biofuels Ltd. Announces Plans to Replace its CFO With Local CFO
11. New Generation Biofuels Set to Join Russell Microcap Index
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3